Invectys will be attending the AACR Annual Meeting 2019. The AACR (American Association for cancer Research) Annual Meeting program covers the latest discoveries…
Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL Financing complements the…
January 7 – 10, 2019 J.P. Morgan 37th Annual Healthcare Conference 2019 San-Francisco The annual J.P. Morgan Healthcare Conference is the largest and most…
The immune system is able to recognize tumor cells and destroy them…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
